Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;41(1):623-628.
doi: 10.1080/0886022X.2019.1635030.

The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy

Peimei Zou  1 , Hang Li  2 , Jianfang Cai  2 , Chao Li  2 , Zhenjie Chen  3 , Xuewang Li  2
Affiliations

The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy

Peimei Zou et al. Ren Fail. 2019 Nov.

Abstract

Objective: The aim of this study is to investigate the role of prophylactic anticoagulation regimens based on low molecular weight heparin (LMWH) or aspirin in thromboembolic events in patients with primary membranous nephropathy (PMN). Methods: A total of 717 patients with PMN were consecutively enrolled in this retrospective study. The propensity score matching method was utilized to adjust for the selection bias inherent in an analysis of outcomes, which was stratified by the anticoagulation prophylaxis regimen. Results: According to the anticoagulation prophylaxis regimen, patients were assigned into three groups: only LMWH therapy (L + A-, n = 53), only aspirin therapy (L - A+, n = 97), and no therapy of LMWH or aspirin (L - A-, n = 567). After performing 1:1 match, 37 patients were selected in the L + A - group and the L - A- group, respectively, and 94 patients were selected in the L - A+ group and the L - A- group, respectively. It showed that the prophylactic use of LMWH had no protective effects on arterial thromboembolic events (ATEs) (10.8% vs. 21.6%, p = .21) or venous thromboembolic events (VTEs) (8.1% vs. 10.8%, p = .69). The incidence of VTEs in the L - A+ group was lower than the L - A- group (2.1% vs. 10.6%, p = .02), while there were no significant differences in the incidences of ATEs between the L - A+ group and the L - A- group (5.3% vs. 7.4%, p = .55). Conclusions: The prophylactic use of LMWH showed no benefits on the incidence of ATEs or VTEs in patients with PMN. Aspirin effectively decreased the incidence of VTEs, without effects on the occurrence of ATEs.

Keywords: Primary membranous nephropathy; arterial; aspirin; low molecular weight heparin; thromboembolism.

PubMed Disclaimer

References

    1. Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118:397–407. - PubMed
    1. Barbour SJ, Greenwald A, Djurdjev O, et al. . Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81:190–195. - PubMed
    1. Lee T, Derebail VK, Kshirsagar AV, et al. . Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int. 2016;89:1111–1118. - PMC - PubMed
    1. Zou PM, Li H, Cai JF, et al. . A cohort study of incidences and risk factors for thromboembolic events in patients with idiopathic membranous nephropathy. Chin Med Sci J. 2018;33:91–99. - PubMed
    1. Mahmoodi BK, ten Kate MK, Waanders F, et al. . High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117:224–230. - PubMed